Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial-Reference-Cited by-同舟云学术

Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial

Published:2017-10-13 Issue:3 Volume:142 Page:618-628
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Kimbung Siker¹²,Markholm Ida¹²,Bjöhle Judith³,Lekberg Tobias³,von Wachenfeldt Anna³,Azavedo Edward³,Saracco Ariel³,Hellström Mats³,Veerla Srinivas¹²,Paquet Eric⁴,Bendahl Pär-Ola¹,Fernö Mårten¹,Bergh Jonas³⁵,Loman Niklas⁶,Hatschek Thomas³⁵,Hedenfalk Ingrid¹²^ORCID,

Affiliation:

1. Department of Clinical Sciences Lund, Division of Oncology and Pathology; Lund University, Skåne University Hospital; Lund Sweden

2. CREATE Health Strategic Center for Translational Cancer Research, Lund University; Lund Sweden

3. Department of Oncology; Karolinska University Hospital; Stockholm Sweden

4. Institute of Bioengineering, School of Life Sciences; Ecole Polytechnique Fédérale de Lausanne; Lausanne CH-1015 Switzerland

5. Department of Oncology-Pathology; Radiumhemmet, Karolinska Institutet; Stockholm Sweden

6. Department of Oncology; Lund University Hospital; Lund Sweden

Funder

Swedish Cancer Society

BioCARE

Governmental Funding of Clinical Research within the National Health Service

Roche Sweden AB

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference39 articles.

1. Preoperative chemotherapy for women with operable breast cancer (Review);Hage;The Cochrane Library,2009

2. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol,2012

3. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

4. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy;Symmans;J Clin Oncol,2007

5. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer;von Minckwitz;Clin Cancer Res.,2013

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer;Nature Communications;2024-05-07

2. An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer;Molecular Oncology;2024-04-26

3. Long noncoding RNA DLEU2 and ROR1 pathway induces epithelial-to-mesenchymal transition and cancer stem cells in breast cancer;Cell Death Discovery;2024-01-31

4. Identification of a Notch transcriptomic signature for breast cancer;Breast Cancer Research;2024-01-03

5. FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters;Journal of Clinical Investigation;2023-11-15